NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis.
Adenocarcinoma of Lung
/ metabolism
Animals
Biopsy
CRISPR-Cas Systems
Carcinogenesis
/ genetics
DNA Methylation
Disease Progression
Epigenesis, Genetic
Epigenomics
Female
Histone-Lysine N-Methyltransferase
/ chemistry
Histones
/ chemistry
Humans
Lung Neoplasms
/ metabolism
Male
Mice
Mice, Inbred NOD
Mice, SCID
Neoplasm Transplantation
Oncogenes
Prognosis
Repressor Proteins
/ chemistry
Signal Transduction
Treatment Outcome
CRISPR interference mouse model
H3K36
KRAS
MEK inhibition
NSD2
chromatin
epigenetics
histone methylation
lung adenocarcinoma
lung cancer
Journal
Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571
Informations de publication
Date de publication:
04 11 2021
04 11 2021
Historique:
received:
11
05
2021
revised:
03
08
2021
accepted:
23
08
2021
pubmed:
24
9
2021
medline:
8
1
2022
entrez:
23
9
2021
Statut:
ppublish
Résumé
The etiological role of NSD2 enzymatic activity in solid tumors is unclear. Here we show that NSD2, via H3K36me2 catalysis, cooperates with oncogenic KRAS signaling to drive lung adenocarcinoma (LUAD) pathogenesis. In vivo expression of NSD2
Identifiants
pubmed: 34555356
pii: S1097-2765(21)00714-0
doi: 10.1016/j.molcel.2021.08.034
pmc: PMC8571016
mid: NIHMS1738209
pii:
doi:
Substances chimiques
Histones
0
Repressor Proteins
0
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
NSD2 protein, human
EC 2.1.1.43
WHSC1 protein, mouse
EC 2.1.1.43
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4481-4492.e9Subventions
Organisme : NCI NIH HHS
ID : R01 CA193466
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA228140
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM139569
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA255936
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA236118
Pays : United States
Organisme : NHGRI NIH HHS
ID : R01 HG007538
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA236949
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests O.G. is a co-scientific founder, consultant, and stockholder of EpiCypher, Inc. and K36 Therapeutics, Inc. P.K.M. is a scientific co-founder, consultant, and stockholder of Amplified Medicines, Inc. and Ikena Oncology, Inc.
Références
Oncologist. 2018 Jun;23(6):740-745
pubmed: 29438093
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Cell. 2020 Jun 8;37(6):834-849.e13
pubmed: 32442403
Methods Mol Biol. 2017;1528:75-95
pubmed: 27854017
Science. 2016 May 13;352(6287):844-9
pubmed: 27174990
Clin Cancer Res. 2011 May 1;17(9):2919-33
pubmed: 21385930
Methods Mol Biol. 1999;119:1-16
pubmed: 10804500
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Cancer Cell. 2003 Dec;4(6):437-50
pubmed: 14706336
Nat Med. 2015 Oct;21(10):1163-71
pubmed: 26390243
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Nature. 2010 Nov 25;468(7323):572-5
pubmed: 21107428
Mol Cell. 2011 May 6;42(3):330-41
pubmed: 21549310
Cold Spring Harb Perspect Med. 2017 Jun 1;7(6):
pubmed: 28193767
Elife. 2017 Jan 16;6:
pubmed: 28079019
J Clin Invest. 2017 Apr 3;127(4):1284-1302
pubmed: 28319045
Cancer Discov. 2020 Jun;10(6):854-871
pubmed: 32188706
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Cell. 2019 Jan 24;176(3):491-504.e21
pubmed: 30612740
Nature. 2014 Jun 12;510(7504):283-7
pubmed: 24847881
Nat Commun. 2019 Oct 24;10(1):4843
pubmed: 31649247
Nat Genet. 2001 Dec;29(4):418-25
pubmed: 11694875
Sci Rep. 2016 Sep 08;6:32952
pubmed: 27604143
Nature. 2021 Feb;590(7846):498-503
pubmed: 33361816
Cancers (Basel). 2021 Feb 15;13(4):
pubmed: 33671873
Leukemia. 2014 Jan;28(1):198-201
pubmed: 23823660
Cancer. 1994 Jun 1;73(11):2727-33
pubmed: 8194013
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Genome Biol. 2014;15(12):550
pubmed: 25516281
Curr Protoc Mol Biol. 2019 Apr;126(1):e85
pubmed: 30688406
Nat Commun. 2018 Dec 5;9(1):5201
pubmed: 30518758
Nature. 2020 Jan;577(7790):421-425
pubmed: 31915379
Lancet. 2016 Sep 3;388(10048):1012-24
pubmed: 27598681
Nature. 2001 Apr 26;410(6832):1111-6
pubmed: 11323676
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
Cancer Discov. 2019 Sep;9(9):1306-1323
pubmed: 31217297
Cell Mol Life Sci. 2019 Aug;76(15):2899-2916
pubmed: 31147750
Nat Rev Drug Discov. 2021 Apr;20(4):265-286
pubmed: 33469207
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Mol Cell. 2011 Nov 18;44(4):609-20
pubmed: 22099308
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Nat Genet. 2005 Jan;37(1):48-55
pubmed: 15608639
Nat Genet. 2013 Nov;45(11):1386-91
pubmed: 24076604
Mol Cell. 2018 Apr 19;70(2):371-379.e5
pubmed: 29606589
Cell. 2013 Sep 12;154(6):1370-9
pubmed: 23992847
Mol Cell. 2015 Oct 15;60(2):319-27
pubmed: 26439302
Bioinformatics. 2011 Jun 15;27(12):1691-2
pubmed: 21493652
Science. 2016 Jun 10;352(6291):1344-8
pubmed: 27229140
Biophys Rep. 2018;4(4):170-177
pubmed: 30310854
J Mol Biol. 1998 Feb 13;276(1):19-42
pubmed: 9514715
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Surg Pathol Clin. 2020 Mar;13(1):17-33
pubmed: 32005431
Nature. 2021 Feb;590(7846):504-508
pubmed: 33536620
PLoS Genet. 2014 Sep 04;10(9):e1004566
pubmed: 25188243
Genes Dev. 2001 Dec 15;15(24):3243-8
pubmed: 11751630
Proc Natl Acad Sci U S A. 2011 May 10;108(19):7902-7
pubmed: 21464299
BMC Biotechnol. 2016 Jan 16;16:4
pubmed: 26772810
Drugs. 2013 Jul;73(11):1245-54
pubmed: 23846731
Nat Struct Mol Biol. 2019 Oct;26(10):880-889
pubmed: 31582846